Better Monitoring of Cisplatin-Induced Ototoxicity Needed

More than half of patients treated with cisplatin develop hearing impairment, but there are few guidelines on the monitoring, prevention, and management of ototoxicity.
Medscape Medical News

source https://www.medscape.com/viewarticle/991347?src=rss

Comments

Popular posts from this blog

RA and RA-ILD Linked to Higher Lung Cancer Risk

Heart Failure Care Outside of ICU Can Lower Cost